or its pharmaceutically acceptable salt wherein X1 represents Pro (P), Ala (A), Gly (G), Gln (Q), Asn (N) or Asp (D); X2 represents aliphatic residue; X3 represents Leu (L) or Phe (F); X4 represents acid residue; X5 represents Leu (L) or Phe (F); X6 represents Leu (L) or Phe (F); X7 represents hydrophilic residue; X8 represents acid or basic residue; X9 represents Leu (L) or Gly (G); X10 represents Leu (L), Trp (W) or Gly (G); X11 represents hydrophilic residue; X12 represents hydrophobic residue;X13 represents Gly (G) or aliphatic residue; X14 represents Leu (L), Trp (W) or Gly (G); X15 represents hydrophilic residue; X16 represents hydrophobic residue; X17 represents hydrophobic residue; X18 represents Gln (Q), Asn (N) or basic residue; X19 represents Gln (Q), Asn (N) or basic residue; X20 represents basic residue; X21 represents aliphatic residue; X22 represents basic residue; X23 is absent or represents basic residue; or (ii) deleted form of structural formula (I) wherein 1-8 residues among are deleted; or (iii) alternated form of structural formula (I) wherein at least one residue among is substituted for another residue by conservative mechanism. Compounds are useful for treatment of diseases associated with dyslipidemia. Invention describes also methods for preparing peptide encoded by these nucleotide sequences, pharmaceutical compositions containing thereof and methods for treatment of diseases associated with dyslipidemia. EFFECT: valuable medicinal properties of peptides, enhanced effectiveness of disease treatment. 68 cl, 10 tbl, 5 dwg, 6 ex"/>
GENE-THERAPEUTIC METHODS FOR ADMINISTRATION OF APOLIPOPROTEIN A-1 AGONISTS AND THEIR USING IN TREATMENT OF DYSLIPIDEMIC DISORDERS
首页>
外国专利>
GENE-THERAPEUTIC METHODS FOR ADMINISTRATION OF APOLIPOPROTEIN A-1 AGONISTS AND THEIR USING IN TREATMENT OF DYSLIPIDEMIC DISORDERS
GENE-THERAPEUTIC METHODS FOR ADMINISTRATION OF APOLIPOPROTEIN A-1 AGONISTS AND THEIR USING IN TREATMENT OF DYSLIPIDEMIC DISORDERS
展开▼
机译：基因疗法治疗APOL脂蛋白A-1激动剂的研究及其在血脂异常治疗中的应用
展开▼
页面导航
摘要
著录项
相似文献
摘要
FIELD: molecular biology, genetic therapy, medicine, amino acids. SUBSTANCE: invention relates to nucleotide sequence encoding agonist of ApoA-1 comprising the following components: (i) 15-29 amino acid peptide that forms amphipathic -helix in the presence of lipids and showing structural formula (I): or its pharmaceutically acceptable salt wherein X1 represents Pro (P), Ala (A), Gly (G), Gln (Q), Asn (N) or Asp (D); X2 represents aliphatic residue; X3 represents Leu (L) or Phe (F); X4 represents acid residue; X5 represents Leu (L) or Phe (F); X6 represents Leu (L) or Phe (F); X7 represents hydrophilic residue; X8 represents acid or basic residue; X9 represents Leu (L) or Gly (G); X10 represents Leu (L), Trp (W) or Gly (G); X11 represents hydrophilic residue; X12 represents hydrophobic residue;X13 represents Gly (G) or aliphatic residue; X14 represents Leu (L), Trp (W) or Gly (G); X15 represents hydrophilic residue; X16 represents hydrophobic residue; X17 represents hydrophobic residue; X18 represents Gln (Q), Asn (N) or basic residue; X19 represents Gln (Q), Asn (N) or basic residue; X20 represents basic residue; X21 represents aliphatic residue; X22 represents basic residue; X23 is absent or represents basic residue; or (ii) deleted form of structural formula (I) wherein 1-8 residues among are deleted; or (iii) alternated form of structural formula (I) wherein at least one residue among is substituted for another residue by conservative mechanism. Compounds are useful for treatment of diseases associated with dyslipidemia. Invention describes also methods for preparing peptide encoded by these nucleotide sequences, pharmaceutical compositions containing thereof and methods for treatment of diseases associated with dyslipidemia. EFFECT: valuable medicinal properties of peptides, enhanced effectiveness of disease treatment. 68 cl, 10 tbl, 5 dwg, 6 ex
展开▼
机译：领域：分子生物学，基因治疗，医学，氨基酸。物质：本发明涉及编码ApoA-1激动剂的核苷酸序列，其包含以下成分：（i）在脂质存在下形成两亲性螺旋并显示结构式（I）的15-29个氨基酸肽： 00000002.GIF“ he =” 14“ imgContent =” undefined“ imgFormat =” GIF“ wi =” 87“ />或其药学上可接受的盐，其中X 1 表示Pro（P），Ala（A ），Gly（G），Gln（Q），Asn（N）或Asp（D）; X 2 代表脂肪族残基; X 3 表示Leu（L）或Phe（F）; X 4 代表酸残基; X 5 表示Leu（L）或Phe（F）; X 6 表示Leu（L）或Phe（F）; X 7 代表亲水性残基; X 8 代表酸或碱性残基; X 9 代表亮（L）或甘氨酸（G）; X 10 代表Leu（L），Trp（W）或Gly（G）; X 11 代表亲水性残基; X 12 代表疏水残基; X 13 代表甘氨酸或脂肪族残基; X 14 代表Leu（L），Trp（W）或Gly（G）; X 15 代表亲水性残基; X 16 代表疏水性残基; X 17 代表疏水性残基; X 18 代表Gln（Q），Asn（N）或碱性残基; X 19 代表Gln（Q），Asn（N）或碱性残基; X 20 表示碱性残基; X 21 代表脂肪族残基; X 22 表示碱性残基; X 23 不存在或代表碱性残基;或（ii）结构式（I）的删除形式，其中<图像文件=“ 00000003.GIF” he =“ 24” imgContent =“ undefined” imgFormat =“ GIF” wi =“ 59” />中的1-8个残基为删除;或（iii）结构式（I）的替代形式，其中中的至少一个残基为通过保守机制取代了另一个残基。该化合物可用于治疗与血脂异常有关的疾病。本发明还描述了制备由这些核苷酸序列编码的肽的方法，含有其的药物组合物以及治疗与血脂异常有关的疾病的方法。功效：肽的宝贵药用特性，增强了疾病治疗的有效性。 68 cl，10 tbl，5 dwg，6 ex
展开▼
